Inhibiting PI3K/Akt/mTOR signaling restored autophagy (Beclin1 and LC3-II expression) and improved pain thresholds, suggesting that mTOR overactivation contributes to metabolic dysfunction in diabetes. Here, MTOR is linked to diabetes mellitus.